Optimal Treatment of Early Stage HER2-positive Breast Cancer

Cancer - United States
doi 10.1002/cncr.31657
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History

Nowotwory
Cancer ResearchOncology
2017English

Current Neoadjuvant Treatment Options for HER2 Positive Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2011English

New Developments in the Treatment of HER2-positive Breast Cancer

Breast Cancer: Targets and Therapy
Oncology
2012English

Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines

BMC Health Services Research
Health Policy
2019English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Optimizing the Management of HER2-positive Early Breast Cancer: The Clinical Reality

Current Oncology
Oncology
2010English

Adjuvant Treatment of HER2-positive Breast Cancer: Winning Efforts Continue to Improve HER2-positive Patient Outcome Long-Term

Breast Cancer Research
Cancer ResearchOncology
2012English

Effects of Herceptin on Circulating Tumor Cells in HER2 Positive Early Breast Cancer

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2015English

Targeted Therapy for HER2 Positive Breast Cancer

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy